Accelsiors CRO

Based on last week’s poll, we deliver based on your votes! 𝟱𝟯% 𝗼𝗳 𝘆𝗼𝘂𝗿 𝘃𝗼𝘁𝗲𝘀 𝗵𝗮𝘃𝗲 𝗰𝗹𝗲𝗮𝗿𝗹𝘆 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗮𝗻 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗲 𝗧𝘂𝗺𝗼𝗿𝘀.  Over recent years, global oncology specialists have embraced 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝗱𝗿𝘂𝗴 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 to treat NETs. These include:  • 𝗦𝗼𝗺𝗮𝘁𝗼𝘀𝘁𝗮𝘁𝗶𝗻 𝗮𝗻𝗮𝗹𝗼𝗴𝘂𝗲𝘀 to reduce hormone levels • 𝗖𝗵𝗲𝗺𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 to target cancer cells • 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 designed to inhibit tumor growth What makes these treatments stand out? They’re 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱, often combined to achieve the best possible outcomes. Join us in advancing treatment options. Request a proposal at bdglobal@accelsiors.com   For more information on our oncology experience >> https://lnkd.in/dDyyEZuh 

Today, on #WorldAIDSDay, we stand in solidarity with the global community to raise awareness, and support those living with HIV. As a global CRO, we are committed to advancing clinical research that drives progress in HIV prevention, treatment, and care. Together, we can work towards a future without AIDS. #ClinicalResearch #HIVAwareness

We're happy to announce our participation in this year’s National Association of Pharmacy Students - Serbia (NAPSer) congress in Serbia!  🗓️𝗪𝗵𝗲𝗻? >>  4-8 December  📍𝗪𝗵𝗲𝗿𝗲? >> Student resort in Zlatibor Join us for an insightful workshop, "𝗙𝗿𝗼𝗺 𝗖𝗼𝗻𝗰𝗲𝗽𝘁 𝘁𝗼 𝗖𝘂𝗿𝗲: 𝗖𝗥𝗢𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁", where Nevena Arsic, our Business Development Associate, and Darko Mitrović, our Senior Regulatory Affairs Associate, will uncover the vital role of CROs in transforming ideas into life-saving medicines. Don’t miss this chance to explore the world of clinical trials, engage in interactive Q&A sessions, and tackle real-world case studies. Discover career opportunities and current industry trends with Accelsiors. 𝗦𝗲𝗲 𝘆𝗼𝘂 𝘁𝗵𝗲𝗿𝗲! 💊 

Let’s shine a light on the rapidly expanding 𝗨.𝗦. 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗺𝗮𝗿𝗸𝗲𝘁 as we conclude U.S. Diabetes Awareness Month. It is estimated to reach 𝗨𝗦𝗗 𝟴.𝟱𝟰 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝟮𝟬𝟮𝟰 and is projected to grow to 𝗨𝗦𝗗 𝟯𝟭.𝟬𝟴 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟰, with an impressive 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟭𝟯.𝟳𝟵%. This growth is driven by the 𝗿𝗶𝘀𝗶𝗻𝗴 𝗽𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀, especially among 𝘆𝗼𝘂𝗻𝗴𝗲𝗿 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀. Additionally, there is an increasing focus on creating personalized insulin therapies to more effectively address patients' needs.    Read our article in a dedicate Spark article, “𝗗𝗲𝗹𝘃𝗶𝗻𝗴 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗗𝘆𝗻𝗮𝗺𝗶𝗰 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗼𝗳 𝗣𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀”, to discover key insights that can help you understanding child-specific therapies. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗵𝗲𝗿𝗲: https://lnkd.in/d3ZJrQ3f

🍂 𝗛𝗮𝗽𝗽𝘆 𝗧𝗵𝗮𝗻𝗸𝘀𝗴𝗶𝘃𝗶𝗻𝗴! 🍂 As we approach this special time of year, we want to take a moment to express our heartfelt gratitude to our incredible partners, colleagues, investigators and patients. Your unwavering support and collaboration inspire us every day. It is your commitment that drives our mission forward, and we are truly thankful for the opportunity to work alongside you in advancing clinical research and improving lives. Wishing you and your loved ones a warm and joyous #Thanksgiving filled with peace and gratitude. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗯𝗲𝗶𝗻𝗴 𝗮 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗼𝘂𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆! 🙏💙

As we wrap up U.S. Diabetes Awareness Month, let’s focus on the 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗼𝗹𝗼𝗴𝘆 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. Where do you see the greatest potential for innovation? 𝗪𝗲’𝗿𝗲 𝗲𝗮𝗴𝗲𝗿 𝘁𝗼 𝗵𝗲𝗮𝗿 𝘆𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀! Take a moment to share your thoughts in our poll. Together, we can drive meaningful changes in the endocrine health sector. 

Let’s make 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵 more than just a time for awareness—let’s turn it into a 𝗺𝗼𝗻𝘁𝗵 𝗼𝗳 𝗮𝗰𝘁𝗶𝗼𝗻! Recent innovations in drug delivery are not just advancing technology; they’re opening doors for transformative partnerships across healthcare. 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿 𝘁𝗵𝗶𝘀: 𝗜𝗻𝗵𝗮𝗹𝗲𝗱 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗮𝗻𝗱 𝗿𝗼𝗯𝗼𝘁𝗶𝗰 𝗽𝗶𝗹𝗹𝘀 — new, non-invasive options that mean rapid absorption without needles. 𝗪𝗲𝗮𝗿𝗮𝗯𝗹𝗲 𝗮𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘀 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝗻𝗱 𝘀𝗺𝗮𝗿𝘁 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗽𝗲𝗻𝘀 — continuous monitoring and precise dosing, changing what’s possible in diabetes management. 𝗪𝗵𝗲𝗿𝗲 𝗱𝗼 𝗖𝗥𝗢𝘀 𝗹𝗶𝗸𝗲 𝗔𝗰𝗰𝗲𝗹𝘀𝗶𝗼𝗿𝘀 𝗳𝗶𝘁 𝗶𝗻? With these innovations, there’s massive potential for collaboration among pharma, research, and technology sectors. 𝗔𝗿𝗲 𝘆𝗼𝘂 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝘄𝗶𝘁𝗵 𝘂𝘀? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗯𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝘄𝗮𝘃𝗲 𝗼𝗳 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗹𝗶𝗳𝗲. >> https://lnkd.in/dnC_K_3p

Accelsiors 𝗪𝗶𝗱𝗲𝗦𝗖𝗢𝗣𝗘 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲™ supports your 𝗲𝗻𝗱𝗼𝗰𝗿𝗶𝗻𝗼𝗹𝗼𝗴𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 by offering one single platform to access to patient data, key trial metrics, and AI-powered analytics. 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗳𝗿𝗲𝗲 𝗱𝗲𝗺𝗼 𝘁𝗼𝗱𝗮𝘆 to experience how the 𝗲𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗪𝗶𝗱𝗲𝗦𝗖𝗢𝗣𝗘 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲™ can elevate your endocrinology clinical trial >> https://lnkd.in/dBeb3CBM

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝗚𝗮𝘆𝗮𝗻𝗲 𝗳𝗼𝗿 𝗮𝗻 𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗡𝗲𝘁𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗥𝗲𝗰𝗲𝗽𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗗𝗮𝘁𝗮 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗟𝗲𝗮𝗱𝗲𝗿𝘀!   If you're in San Francisco and attending this special event organized by 𝗠𝗲𝗱𝗿𝗶𝗼, do not hesitate to get in touch with our 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗨𝗦𝗔, Gayane Nazaretyan. This is a fantastic opportunity to engage in meaningful conversations and gain expert knowledge.   We look forward to seeing you there!

𝗔𝘀 𝘄𝗲 𝗺𝗮𝗿𝗸 𝗪𝗼𝗿𝗹𝗱 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗗𝗮𝘆, 𝗹𝗲𝘁’𝘀 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲 𝘁𝗵𝗲 𝘃𝗶𝘁𝗮𝗹 𝗿𝗼𝗹𝗲 𝘁𝗵𝗮𝘁 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗶𝗻𝘀𝘂𝗹𝗶𝗻 𝗽𝗹𝗮𝘆𝘀 𝗶𝗻 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁. This innovative alternative not only delivers effective therapies but also helps reduce the financial burden on patients and expand market accessibility.    At Accelsiors, we’ve dedicated over 20 years to pioneering 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, offering deep expertise in strategic guidance and clinical trial management. 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝗮𝗯𝗼𝘂𝘁 𝗵𝗼𝘄 𝗼𝘂𝗿 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗰𝗮𝗻 𝗯𝗲 𝗯𝗲𝗻𝗲𝗳𝗶𝗰𝗶𝗮𝗹 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹? 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗵𝗲𝗿𝗲 >> https://lnkd.in/dfGc_2TC  #WorldDiabetesDay #GlobalBiosimilarsWeek